Here, we confirmed new strategies in both HER2+ breast cancer and TNBC cell lines, not only by using the on-target effect of ERBB family protein inhibition but also by suppressing the compensatory PI3K-Akt-mTOR and MAPK pathways. The gene discussed is PIK3CA; the disease is breast carcinoma.